Burosumab
Based on 1 publication(s) in Google Scholar
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.20%
- CAS No.: 1610833-03-8
- 분자량:144.08 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
FGF23
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4-week-old male Hyp mice (C57BL/6J background) with X-linked hypophosphatemia caused by PHEX gene mutation[3]
-
Dosage:4 and 16 mg/kg
-
Administration:Subcutaneous injection; once weekly; 2 months
-
Result:Significantly improved dentin/cementum volume, reduced pulp chamber volume to wild-type levels, particularly with 16 mg/kg.
Enhanced alveolar bone volume fraction and mineral density, restored periodontal ligament attachment and acellular cementum continuity.
Decreased osteoid and cementoid accumulation.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized FGF23-N-His can bind Burosumab. The EC50 for this effect is 241 ng/mL.
Product Details
-
CAS No. 1610833-03-8
-
Accession Q9GZV9
-
Synonyms KRN23; N5KG1_C10_LH; UX-023
-
분자량 144.08 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1(D356E/L358M) kappa
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.20%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
선적
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biology (Basel)
FGF23 Controls Myocardial Fibrosis Progression via Promoting Cardiac Fibroblast Proliferation and Activation in Mice. [Abstract]2026 Mar 27;15(7):539. PMID: 41972542
순도&문서
References
[1]. Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. Front Endocrinol (Lausanne). 2020 May 28;11:338. [Content Brief]
[2]. Colangelo L, et al. Appropriate dosing of burosumab in tumor-induced osteomalacia. Osteoporos Int. 2022 Dec 1. [Content Brief]
[3]. Lira Dos Santos EJ, et al. Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia. Int J Oral Sci. 2023 Dec 6;15(1):53. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)